TOP TEN perturbations for 1047_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1047_s_at
Selected probe(set): 213380_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1047_s_at (213380_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-3.5710325Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):-3.457572Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
collecting duct carcinoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.9208097Number of Samples:2 / 2
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
nephroblastoma study 2 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.8781319Number of Samples:4 / 2
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-2.8318434Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-2.7891655Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):2.7788696Number of Samples:2 / 3
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
colorectal cancer study 1 / normal colon tissue
Relative Expression (log2-ratio):-2.6417665Number of Samples:6 / 6
| Experimental | colorectal cancer study 1 |
| Laser microdissected human colorectal cancer sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
expO lung cancer study 1 (squamous cell carcinoma, NOS; primary) / expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.5551205Number of Samples:40 / 2
| Experimental | expO lung cancer study 1 (squamous cell carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the lung of patients with squamous cell carcinoma (NOS). | |
| Control | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). |
oxyphilic adenoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.54453Number of Samples:4 / 2
| Experimental | oxyphilic adenoma study 1 |
| Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
Organism: Homo sapiens
Gene: 1047_s_at
Selected probe(set): 215563_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1047_s_at (215563_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-4.2951536Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
renal cell carcinoma study 1 (prim. tumor) / adjacent kidney tissue
Relative Expression (log2-ratio):-4.0468225Number of Samples:3 / 3
| Experimental | renal cell carcinoma study 1 (prim. tumor) |
| Tumor tissue from the primary tumor of patients with renal cell carcinoma (RCC). | |
| Control | adjacent kidney tissue |
| Histologically normal tissue from an unaffected site (renal tubules) of patients with renal cell carcinoma (RCC) of the clear cell type. |
nephroblastoma study 2 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-4.0446577Number of Samples:4 / 2
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
renal cell carcinoma study 1 (metastasis) / adjacent kidney tissue
Relative Expression (log2-ratio):-4.044071Number of Samples:3 / 3
| Experimental | renal cell carcinoma study 1 (metastasis) |
| Tumor tissue from metastases of patients with renal cell carcinoma (RCC). | |
| Control | adjacent kidney tissue |
| Histologically normal tissue from an unaffected site (renal tubules) of patients with renal cell carcinoma (RCC) of the clear cell type. |
renal cell carcinoma study 4 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.9172554Number of Samples:26 / 3
| Experimental | renal cell carcinoma study 4 |
| Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.8850746Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
renal cell carcinoma study 4 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-3.6667595Number of Samples:26 / 2
| Experimental | renal cell carcinoma study 4 |
| Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
collecting duct carcinoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-3.6345787Number of Samples:2 / 2
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
clear cell renal cell carcinoma study 4 (stage 4) / normal kidney tissue
Relative Expression (log2-ratio):-3.537488Number of Samples:14 / 69
| Experimental | clear cell renal cell carcinoma study 4 (stage 4) |
| Primary tumor tissue from patients with stage 4 clear cell renal cell carcinoma (ccRCC). | |
| Control | normal kidney tissue |
| Normal kidney tissue samples obtained from healthy individuals. |
renal cell carcinoma study 5 (papillary type) / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.5363398Number of Samples:19 / 3
| Experimental | renal cell carcinoma study 5 (papillary type) |
| Tumor tissue samples from the kidney of patients with papillary renal cell carcinoma (pRCC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
Organism: Homo sapiens
Gene: 1047_s_at
Selected probe(set): 216320_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1047_s_at (216320_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-2.9821682Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):-2.4762068Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
collecting duct carcinoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.2671795Number of Samples:2 / 2
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-2.2563467Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.1735783Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
succinate dehydrogenase B depletion study 1 (siRNA) / control siRNA transfected Hep3B cell sample
Relative Expression (log2-ratio):-2.1510353Number of Samples:3 / 3
| Experimental | succinate dehydrogenase B depletion study 1 (siRNA) |
| Hep3B cells stably transfected with short hairpin vectors containing an siRNA directed to the subunit B of the succinate dehydrogenase. | |
| Control | control siRNA transfected Hep3B cell sample |
| Hep3B cells stably transfected with empty siRNA expression vector (pU6). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.1257324Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; liver)
Relative Expression (log2-ratio):-2.0842733Number of Samples:7 / 3
| Experimental | breast cancer study 42 (metastase; lymph node) |
| Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma. | |
| Control | breast cancer study 42 (metastase; liver) |
| Metastatic tumor tissue obtained from the liver of patients with primary breast adenocarcinoma. |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.070798Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
HCC study 23 (portal vein infiltration) / adjacent liver tissue
Relative Expression (log2-ratio):-2.0672379Number of Samples:3 / 10
| Experimental | HCC study 23 (portal vein infiltration) |
| Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. | |
| Control | adjacent liver tissue |
| Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. |
Organism: Homo sapiens
Gene: 1047_s_at
Selected probe(set): 216320_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1047_s_at (216320_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-2.9821682Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):-2.4762068Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
collecting duct carcinoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.2671795Number of Samples:2 / 2
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-2.2563467Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.1735783Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
succinate dehydrogenase B depletion study 1 (siRNA) / control siRNA transfected Hep3B cell sample
Relative Expression (log2-ratio):-2.1510353Number of Samples:3 / 3
| Experimental | succinate dehydrogenase B depletion study 1 (siRNA) |
| Hep3B cells stably transfected with short hairpin vectors containing an siRNA directed to the subunit B of the succinate dehydrogenase. | |
| Control | control siRNA transfected Hep3B cell sample |
| Hep3B cells stably transfected with empty siRNA expression vector (pU6). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.1257324Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; liver)
Relative Expression (log2-ratio):-2.0842733Number of Samples:7 / 3
| Experimental | breast cancer study 42 (metastase; lymph node) |
| Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma. | |
| Control | breast cancer study 42 (metastase; liver) |
| Metastatic tumor tissue obtained from the liver of patients with primary breast adenocarcinoma. |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.070798Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
HCC study 23 (portal vein infiltration) / adjacent liver tissue
Relative Expression (log2-ratio):-2.0672379Number of Samples:3 / 10
| Experimental | HCC study 23 (portal vein infiltration) |
| Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. | |
| Control | adjacent liver tissue |
| Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. |